Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

P130 Impact of left ventricular hypertrophy on mortality in COPD

Title: P130 Impact of left ventricular hypertrophy on mortality in COPD
Authors: Short, PM; Anderson, WJ; Elder, DH; Struthers, AD; Lipworth, BJ
Publisher Information: BMJ Publishing Group Ltd
Publication Year: 2013
Collection: HighWire Press (Stanford University)
Subject Terms: COPD exacerbations: the heart of the matter
Description: Introduction and Objectives Left ventricular hypertrophy (LVH) is a significant risk factor of cardiovascular disease and is associated with increased mortality. Previous studies have shown an increased prevalence of LVH in normoxaemic COPD patients. The impact of LVH on mortality in COPD is yet to be established. We evaluated the impact of LVH on mortality in COPD patients by measurement of left ventricular dimensions by echocardiography. Methods We performed a retrospective cohort study utilising a NHS database of COPD patients (TARDIS) in Tayside, Scotland between 2001 and 2010 that was linked with NHS Tayside databases regarding echocardiograms, pharmacy prescription and the General Register Office for Scotland death registry. Left ventricular internal diastolic diameter (LVIDd) and left ventricular mass index (LVMI) were measured. Increased LVIDd was defined as > 5.3 cm (female) and > 5.9 cm (male). LVMI was obtained by correcting the left ventricular mass to body surface area. LVH was defined as an LVMI of >95 g/m2 (female) and > 115 g/m2 (male). Patients with aortic valve disease were excluded from the analysis. The impact of increased LVIDd and LVMI on mortality were evaluated by Kaplan Meir testing and Cox Regression analyses after inclusion of covariates (age, FEV 1 %, SaO 2 %, history of diabetes and cardiovascular disease, medication (aspirin, ACE-inhibitor, statin, beta blocker). Results 617 patients were included for analysis. Mean (SD) age at diagnosis, 70 (9); mean FEV 1 % (SD), 60.6 (19.3); mean resting SaO 2 % (SD), 92.7 (10). Mean follow up 4.5 years. Increased LVIDd was not associated with increased mortality, X2 = 0.767, p = 0.381. Increased LVMI was associated with a significant increased risk of mortality, X2 = 5.447, p = 0.02. with an adjusted HR (95%CI) of 1.542 (1.068–2.228), p = 0.021. (see graph below). Conclusion The presence of left ventricular hypertrophy, demonstrated by elevated left ventricular mass index is associated with a significantly increased risk of mortality ...
Document Type: text
File Description: text/html
Language: English
Relation: http://thorax.bmj.com/cgi/content/short/68/Suppl_3/A134-a; http://dx.doi.org/10.1136/thoraxjnl-2013-204457.280
DOI: 10.1136/thoraxjnl-2013-204457.280
Availability: http://thorax.bmj.com/cgi/content/short/68/Suppl_3/A134-a; https://doi.org/10.1136/thoraxjnl-2013-204457.280
Rights: Copyright (C) 2013, BMJ Publishing Group Ltd
Accession Number: edsbas.755F48EC
Database: BASE